ALLEN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Atrion Corporation (Nasdaq: ATRI) today announced an increase in its quarterly cash dividend from $2.15 per share to $2.20 per share. At today’s meeting, the Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on September 29, 2023, to stockholders of record at the close of business on September 15, 2023.
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
Contact:
Cindy Ferguson
Vice President and Chief Financial Officer
(972) 390-9800
| Last Trade: | US$459.92 |
| Daily Volume: | 0 |
| Market Cap: | US$809.460M |
August 08, 2024 May 28, 2024 May 10, 2024 February 29, 2024 November 07, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
